Celecoxib + Carboplatin/Paclitaxel+Radiation Therapy [clinicaltrials_resource:NCT00581971/group/P1]
Patients with locally advanced head and neck cancer will be treated with weekly carboplatin, paclitaxel, and concurrent radiotherapy. Radiotherapy will be delivered at 1.8 Gy every day, to a maximum dose of 70.2 Gy. Carboplatin will be dosed at AUC=2.0, while paclitaxel will be dosed at 30mg/m2. Celecoxib will be delivered at 400mg twice daily, starting 1 week prior to the onset of radiotherapy to establish constant blood levels.
participant flow for clinicaltrials:NCT00581971 [clinicaltrials_resource:416e3552747be213854cf4a7c42be17b]participant counts in P1 for milestone 2 of NCT00581971 [clinicaltrials_resource:NCT00581971/milestone/1/p/1]participant counts in P1 for milestone 3 of NCT00581971 [clinicaltrials_resource:NCT00581971/milestone/2/p/1]participant counts in P1 for milestone 4 of NCT00581971 [clinicaltrials_resource:NCT00581971/milestone/3/p/1]
group [clinicaltrials_vocabulary:group]
Celecoxib + Carboplatin/Paclitaxel+Radiation Therapy [clinicaltrials_resource:NCT00581971/group/P1]
Patients with locally advanced head and neck cancer will be treated with weekly carboplatin, paclitaxel, and concurrent radiotherapy. Radiotherapy will be delivered at 1.8 Gy every day, to a maximum dose of 70.2 Gy. Carboplatin will be dosed at AUC=2.0, while paclitaxel will be dosed at 30mg/m2. Celecoxib will be delivered at 400mg twice daily, starting 1 week prior to the onset of radiotherapy to establish constant blood levels.
Bio2RDF identifier
NCT00581971/group/P1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00581971/group/P1
group id [clinicaltrials_vocabulary:group-id]
description
Patients with locally advanced ...... tablish constant blood levels.
@en
identifier
clinicaltrials_resource:NCT00581971/group/P1
title
Celecoxib + Carboplatin/Paclitaxel+Radiation Therapy
@en
type
label
Celecoxib + Carboplatin/Paclit ...... resource:NCT00581971/group/P1]
@en